Overview

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Status:
Recruiting
Trial end date:
2030-09-15
Target enrollment:
Participant gender:
Summary
Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AbClon
Treatments:
Gossypol acetic acid